Analysis of the Effect of Levosimendan on Acute Myocardial Infarction Combined with Heart Failure in Elderly People
Objective To study the effectiveness and safety of levosimendan in the treatment of elderly patients with acute myocardial infarction combined with heart failure.Methods A total of 42 elderly patients with acute myocardial infarction complicated with heart failure admitted to the Department of Cardiology,Wuxi Second People's Hospital from January 2020 to January 2023 were selected as the research objects.They were divided into control group and ob-servation group by random number table method,with 21 cases in each group.The control group was given conven-tional treatment,and the observation group was given levosimendan once for 24 h on the basis of conventional treat-ment.The two groups were compared in terms of clinical efficacy,vital signs,serum N-terminal brain natriuretic pep-tide(NT-proBNP),echocardiography-related indexes,the occurrence of adverse reactions such as hypotension or tachyarrhythmia,and the occurrence of major adverse event rate(MACE)during the 6 month follow-up.Results Be-fore treatment,the vital signs(heart rate,systolic blood pressure,diastolic blood pressure,respiratory rate),brain natri-uretic peptide levels,and cardiac function(left ventricular ejection fraction,left ventricular end diastolic diameter,and left ventricular short axis shortening rate)were compared between the two groups of patients,and there was no sta-tistically significant difference(all P>0.05).After treatment,the total effective rate of treatment the observation group was higher than that of the control group,the level of NT-proBNP was lower than that of the control group,and the heart function was better than that of the control group,the differences were statistically significant(all P<0.05).The incidence of adverse reactions in both groups was relatively low,and the difference was not statistically significant(P>0.05).The hospitalization time of the observation group was shorter than that of the control group,and the treatment cost was less than that of the control group,the differences were statistically significant(both P<0.05).There was no statistically significant difference in several long-term outcomes(mortality rate,readmission rate,incidence of cardio-vascular adverse events)(all P>0.05).Conclusion Levosimendan is more effective in elderly acute myocardial infarc-tion combined with heart failure patients,can rapidly improve clinical symptoms,reduce brain natriuretic peptide level,improve cardiac function,no increase in hypotension,atrial fibrillation,ventricular tachycardia and other ad-verse reactions,but no improvement for the long-term prognosis,which can shorten the number of days of hospitaliza-tion,reduce the patient's health care burden.
LevosimendanAcute myocardial infarction in advanced ageHeart failureClinical efficacyCardiac functionLong-term prognosis
NETL
NSTL
万方数据
维普
